Vectus Biosystems Ltd
VBS
Company Profile
Business description
Vectus Biosystems Ltd is an emerging biotechnology company based in Sydney, Australia. The company has developed and patented various novel compounds for the treatment of chronic fibrosis, including cardio, kidney, liver, and lung fibrosis. Its drug candidate VB0004, is aimed at inhibiting and reversing the loss of functional tissue due to fibrosis, is in its human trials phase.
Contact
26-34 Dunning Avenue
Unit 5, Ground Floor
Rosebery
SydneyNSW2018
AUST: +61 283441300
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
Employees
Stocks News & Analysis
stocks
Anthropic and OpenAI face commodification threats. Here’s what to watch for
Frontier AI labs face a three-pronged set of challenges.
stocks
Berkshire Hathaway: Abel pushes into new territory with Bending Spoons investment
We think it is a sign that the firm is finally moving out of its comfort zone to find places to put capital to work.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,897.60 | 78.10 | -0.87% |
| CAC 40 | 7,868.05 | 88.65 | -1.11% |
| DAX 40 | 25,319.77 | 302.84 | -1.18% |
| Dow JONES (US) | 51,966.03 | 36.38 | -0.07% |
| FTSE 100 | 10,764.69 | 117.21 | -1.08% |
| HKSE | 24,186.83 | 124.11 | 0.52% |
| NASDAQ | 26,430.89 | 290.85 | 1.11% |
| Nikkei 225 | 64,483.37 | 433.33 | -0.67% |
| NZX 50 Index | 13,657.61 | 5.54 | 0.04% |
| S&P 500 | 7,690.73 | 31.29 | 0.41% |
| S&P/ASX 200 | 8,764.60 | 81.10 | -0.92% |
| SSE Composite Index | 3,716.28 | 8.81 | 0.24% |